Deng Hongkui's group and collaborators confirmed the safety and efficacy of human pluripotent stem cell-derived islet cells in the treatment of diabetes in a non-human primate model

? ? ? On February 4, 2022, Deng Hongkui's research group from Peking University School of Basic Medicine, Peng Xiaozhong's research group from Chinese Academy of Medical Sciences/Peking Union Medical College, and Shen Zhongyang's research group from Tianjin First Central Hospital jointly published a paper entitled Human Pluripotent in Nature Medicine The research paper of Stem Cell-derived Islets Ameliorate Diabetes in Nonhuman Primates, this research first further optimized and improved the preparation scheme for the differentiation of human pluripotent stem cells into islet cells on the basis of the original work, and obtained a functionally mature source of human pluripotent stem cell differentiation The islet cells were further transplanted into non-human primate diabetic animal models, and the safety and efficacy of islets differentiated from human pluripotent stem cells in the treatment of diabetes were systematically evaluated

? ? ? Human pluripotent stem cells have the potential to proliferate and differentiate into functional cells indefinitely, which makes the use of human pluripotent stem cells-derived functional cells promising for the treatment of many major diseases

? ? ? As early as 2005, Deng Hongkui's research group of Peking University took the lead in adopting the strategy of simulating the in vivo development of the pancreas and inducing differentiation step by step, using Activin A to induce the differentiation of mouse pluripotent stem cells into endoderm cells, and then using retinoic acid ( Retinoic acid, RA) induced cells to specialize towards pancreatic fate, and finally added factors that promote pancreatic β-cell differentiation, and induced mouse pluripotent stem cells to differentiate into pancreatic β-cells step by step in vitro (Shi et al, Stem Cells, 2005)

? ? ? In 2006, American Novocell Company (now renamed ViaCyte Company) adopted Actinvin A and RA reported by Deng Hongkui's research group, and further added other inducing factors for step-by-step treatment to induce human pluripotent stem cells into insulin-secreting cells ( D'Amour et al, Nat Biotechnol, 2006)

? ? ? In this study, Deng Hongkui's research group has greatly improved the differentiation protocol of human pluripotent stem cells into islet cells, focusing on solving the problem of how to efficiently induce the fate specialization from pancreatic precursor cells to islet endocrine cells (Fig.

Figure 1.

Figure 2.

? ? ? On this basis, the research team further transplanted islet cells differentiated from human pluripotent stem cells into a diabetic non-human primate model to observe its long-term safety and efficacy

Figure 3.

? ? ? Recently, some important advances have been made in the treatment of diabetes using cells differentiated from human pluripotent stem cells

? ? ? This study successfully demonstrated the safety and efficacy of human pluripotent stem cell-derived islet cells in the treatment of diabetes in a non-human primate model

? ? ? Professor Deng Hongkui from Peking University School of Basic Medicine, Professor Peng Xiaozhong from Chinese Academy of Medical Sciences/Peking Union Medical College, and Professor Shen Zhongyang from Tianjin First Central Hospital are the co-corresponding authors of the paper

? ? ? ? ? ? ? ? ? ? ? ? (Peking University School of Basic Medicine)

[Original link]? https://